Safety assessment of ustekinumab in inflammatory bowel disease: a real-world analysis based on the FDA adverse event reporting system (FAERS)

This study provides comprehensive real-world insights into the safety of UST use in IBD treatment, corroborating known adverse reactions and identifying additional potential risks. Robust pharmacovigilance and long-term monitoring are essential to support personalized UST therapy and facilitate informed risk-benefit assessments.

Authors

Sujun Gao
Likang Xu
Zhenkai Huang
Gong Chen (ORCID: https://orcid.org/0000-0002-1738-0025)
Chao Sun (ORCID: https://orcid.org/0000-0001-7222-4028)
Yang Yu (ORCID: https://orcid.org/0009-0002-3624-3728)

Institutions

Northern Jiangsu People's Hospital (CN)
Yangzhou University (CN)

Publication Details

Journal: European journal of medical research
Published: 2025-12-13
DOI: https://doi.org/10.1186/s40001-025-03676-z
Citations: 1
Primary Topic: Pharmacovigilance and Adverse Drug Reactions
Type: article
Field-Weighted Citation Impact: 1.31

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Safety assessment of ustekinumab in inflammatory bowel disease: a real-world analysis based on the FDA adverse event reporting system (FAERS)

Sujun Gao, Likang Xu, Zhenkai Huang, Gong Chen et al.

Dec 13, 2025

1 citations

European journal of medical research

Pharmacovigilance and Adverse Drug Reactions

1.31

article

Safety assessment of ustekinumab in inflammatory bowel disease: a real-world analysis based on the FDA adverse event reporting system (FAERS)

Sujun Gao, Likang Xu, Zhenkai Huang, Gong Chen, Chao Sun, Yang Yu

December 13, 2025article en

1 citations

Abstract

This study provides comprehensive real-world insights into the safety of UST use in IBD treatment, corroborating known adverse reactions and identifying additional potential risks. Robust pharmacovigilance and long-term monitoring are essential to support personalized UST therapy and facilitate informed risk-benefit assessments.

European journal of medical researchVol. 31(1)

Northern Jiangsu People's Hospital (CN), Yangzhou University (CN)

Openalex Percentile: Top 16%

Pharmacovigilance and Adverse Drug Reactions

1.31

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Safety assessment of ustekinumab in inflammatory bowel disease: a real-world analysis based on the FDA adverse event reporting system (FAERS) — Sujun Gao, Likang Xu, et al. · European journal of medical research (2025) | TGRS Research Map | TGRS